ZA200804868B - Anti-OX40L antibodies and methods using same - Google Patents

Anti-OX40L antibodies and methods using same

Info

Publication number
ZA200804868B
ZA200804868B ZA200804868A ZA200804868A ZA200804868B ZA 200804868 B ZA200804868 B ZA 200804868B ZA 200804868 A ZA200804868 A ZA 200804868A ZA 200804868 A ZA200804868 A ZA 200804868A ZA 200804868 B ZA200804868 B ZA 200804868B
Authority
ZA
South Africa
Prior art keywords
methods
same
ox40l antibodies
ox40l
antibodies
Prior art date
Application number
ZA200804868A
Other languages
English (en)
Inventor
Martin Flavius
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of ZA200804868B publication Critical patent/ZA200804868B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA200804868A 2005-12-16 2006-12-15 Anti-OX40L antibodies and methods using same ZA200804868B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75137705P 2005-12-16 2005-12-16

Publications (1)

Publication Number Publication Date
ZA200804868B true ZA200804868B (en) 2009-10-28

Family

ID=38616368

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200804868A ZA200804868B (en) 2005-12-16 2006-12-15 Anti-OX40L antibodies and methods using same

Country Status (18)

Country Link
US (2) US7812133B2 (fr)
EP (1) EP1973949A2 (fr)
JP (1) JP2009519718A (fr)
KR (1) KR20080080639A (fr)
CN (1) CN101374865A (fr)
AR (1) AR057253A1 (fr)
AU (1) AU2006343459A1 (fr)
BR (1) BRPI0621065A2 (fr)
CA (1) CA2633602A1 (fr)
CR (1) CR10069A (fr)
EC (1) ECSP088543A (fr)
IL (1) IL191820A0 (fr)
MA (1) MA30153B1 (fr)
NO (1) NO20083147L (fr)
RU (1) RU2426744C2 (fr)
TW (1) TW200732349A (fr)
WO (1) WO2007133290A2 (fr)
ZA (1) ZA200804868B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291331B1 (en) 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
EP2041756B1 (fr) 2006-07-14 2015-05-13 FEI Company Système de faisceau ionique focalisé à plasma multisource
RU2009135824A (ru) * 2007-02-27 2011-04-10 Дженентек, Инк. (Us) Антитела-антагонисты против ох40 и их применение в лечении воспалительных и аутоиммунных заболеваний
US20090309617A1 (en) * 2007-08-24 2009-12-17 Ye Fang Biosensor antibody functional mapping
WO2009141239A1 (fr) * 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag Formulation pharmaceutique comprenant un anticorps contre ox40l, utilisations de celle-ci
US8518405B2 (en) * 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
EP2513145B1 (fr) 2009-12-14 2018-01-24 Ablynx N.V. Domaines variables uniques de liaison anti-ox40l, construits et application therapeutique
WO2012015696A1 (fr) * 2010-07-26 2012-02-02 Baylor Research Institute Lymphopoïétine stromale thymique (tspl) et ligand ox40 dans le cancer
ME02678B (fr) 2010-08-23 2017-06-20 Univ Texas Anticorps anti-ox40 et leurs procédés d'utilisation
US9845362B2 (en) 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
AR083847A1 (es) * 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
RS57087B1 (sr) 2011-04-21 2018-06-29 Bristol Myers Squibb Co Polipeptidi antitela koji antagonizuju cd40
AU2012299421B2 (en) * 2011-08-23 2016-02-04 Board Of Regents, The University Of Texas System Anti-OX40 antibodies and methods of using the same
KR102162323B1 (ko) * 2013-09-09 2020-10-06 캐님가이드 테라퓨틱스 에이비 면역계 조절제
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
JP2017165652A (ja) * 2014-06-30 2017-09-21 国立大学法人東北大学 新規抗ヒトｏｘ４０リガンド抗体、及びこれを含む抗インフルエンザ薬
CN107074951B (zh) * 2014-08-04 2021-08-03 贝勒研究院 拮抗性抗-ox40l抗体及其使用方法
US11554181B2 (en) 2014-09-05 2023-01-17 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
US9512229B2 (en) 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
US9434785B1 (en) * 2015-04-30 2016-09-06 Kymab Limited Anti-human OX40L antibodies and methods of treating graft versus host disease with the same
ES2937020T3 (es) * 2015-03-03 2023-03-23 Kymab Ltd Anticuerpos, usos y métodos
US10881709B2 (en) 2015-03-06 2021-01-05 Canimguide Therapeutics Ab Immune system modulators and compositions
EP3292152A1 (fr) 2015-05-07 2018-03-14 Agenus Inc. Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
WO2017096179A1 (fr) 2015-12-02 2017-06-08 Agenus Inc. Anticorps et leurs méthodes d'utilisation
DE102016105069A1 (de) 2016-03-18 2017-09-21 Eberhard Karls Universität Tübingen Medizinische Fakultät Antivirale Immuntherapie durch Membranrezeptorligation
EP3443984A4 (fr) 2016-04-15 2019-04-10 Pontificia Universidad Católica De Chile Composition pharmaceutique pour diminuer les symptômes et la maladie de l'infection respiratoire causée par le métapneumovirus humain (hmpv) qui comprend au moins un agent neutralisant la fonction des molécules tspl et/ou tslpr, et/ou ox40l et/ou cd177, et un excipient pharmaceutiquement acceptable, et leur utilisation
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
RU2764548C2 (ru) 2016-08-09 2022-01-18 Кимаб Лимитед Анти-icos антитела
WO2018083248A1 (fr) 2016-11-03 2018-05-11 Kymab Limited Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
WO2018089628A1 (fr) 2016-11-09 2018-05-17 Agenus Inc. Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
JP7479281B2 (ja) 2017-11-24 2024-05-08 ユーキュア・（ベイジン）・バイオファーマ・カンパニー・リミテッド 抗ｏｘ４０抗体及びその用途
US11629189B2 (en) 2017-12-19 2023-04-18 Kymab Limited Bispecific antibody for ICOS and PD-L1
GB202012331D0 (en) * 2020-08-07 2020-09-23 Petmedix Ltd Therapeutic antibodies
CN114437228B (zh) * 2020-10-30 2024-02-06 中国科学院生物物理研究所 一种il-2与抗体亚单位构成的双功能融合蛋白
US20230235069A1 (en) * 2021-08-10 2023-07-27 Kymab Limited Treatment of atopic dermatitis
WO2023152486A1 (fr) * 2022-02-09 2023-08-17 Petmedix Ltd Anticorps thérapeutiques

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457035A (en) * 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5821332A (en) 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
US6242566B1 (en) 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
JP3914342B2 (ja) 1997-09-25 2007-05-16 武田薬品工業株式会社 ｇｐ３４結合阻害物を有効成分として含有する医薬組成物
CA2410188A1 (fr) * 2000-06-06 2001-12-13 Idec Pharmaceutical Corporation Anticorps non agonistiques diriges contre gp 39 humaine, compositions les contenant et leur utilisation therapeutique
FR2822846B1 (fr) * 2001-04-03 2004-01-23 Technopharm Procede de preparation et de selection d'anticorps
GB0123276D0 (en) 2001-09-27 2001-11-21 Imp College Innovations Ltd Uses of agents that bind immune-system components
JP3926596B2 (ja) 2001-09-28 2007-06-06 独立行政法人科学技術振興機構 Ｏｘ４０ｌ遺伝子を導入した自己免疫疾患モデル非ヒト哺乳動物
WO2003059245A2 (fr) 2001-12-18 2003-07-24 J & J Research Pty Ltd Methode de traitement de l'asthme
IL164376A0 (en) 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
PL376536A1 (pl) 2002-08-28 2006-01-09 Immunex Corporation Kompozycje i sposoby leczenia chorób układu sercowo-naczyniowego
US7291331B1 (en) 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
AU2005229009A1 (en) * 2004-03-23 2005-10-13 Amgen, Inc. Monoclonal antibodies specific for human OX40L (CD 134L)
JP2006081061A (ja) * 2004-09-13 2006-03-23 Alpine Electronics Inc 音声出力装置及び音声／映像出力装置
TWI309240B (en) * 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
RU2009135824A (ru) 2007-02-27 2011-04-10 Дженентек, Инк. (Us) Антитела-антагонисты против ох40 и их применение в лечении воспалительных и аутоиммунных заболеваний

Also Published As

Publication number Publication date
US20100272738A1 (en) 2010-10-28
RU2008129111A (ru) 2010-01-27
WO2007133290A8 (fr) 2008-03-27
CN101374865A (zh) 2009-02-25
JP2009519718A (ja) 2009-05-21
AU2006343459A1 (en) 2007-11-22
EP1973949A2 (fr) 2008-10-01
CA2633602A1 (fr) 2007-11-22
RU2426744C2 (ru) 2011-08-20
WO2007133290A3 (fr) 2008-01-10
US7812133B2 (en) 2010-10-12
US20090053230A1 (en) 2009-02-26
CR10069A (es) 2008-10-10
BRPI0621065A2 (pt) 2011-11-29
NO20083147L (no) 2008-09-16
ECSP088543A (es) 2008-07-30
IL191820A0 (en) 2008-12-29
WO2007133290A2 (fr) 2007-11-22
KR20080080639A (ko) 2008-09-04
MA30153B1 (fr) 2009-01-02
TW200732349A (en) 2007-09-01
AR057253A1 (es) 2007-11-21

Similar Documents

Publication Publication Date Title
IL272883A (en) Monoclonal antibodies and their uses
ZA200804868B (en) Anti-OX40L antibodies and methods using same
IL222922A (en) Antibodies against neurophilin-1 and their use
ZA200805741B (en) Anti-MN antibodies and methods of using same
PT1973950E (pt) Anticorpos anti-epbh4 e métodos que os utilizam
AP2008004471A0 (en) Anti-Alpha2 Intergin antibodies and their uses
IL182554A0 (en) Anti-addl antibodies and uses thereof
IL184024A0 (en) Irta-5 antibodies and their uses
EP1915177A4 (fr) Anticorps d'alpha-synucléine et techniques associées
PT2343320T (pt) Anticorpos anti-gitr e as suas utilizações
IL178277A0 (en) Irta-5 antibodies and their uses
IL187710A0 (en) Anti-trkb monoclonal antibodies and uses thereof
EP1765396A4 (fr) Anticorps
EP1846032A4 (fr) Luca2 et anticorps s'y liant
HK1107402A1 (en) Kid31 and antibodies that bind thereto kid31
IL231891A (en) Anti-ephrinb2 antibodies and methods for their use
ZA200703406B (en) Anti-ADDL antibodies and uses thereof
GB0420466D0 (en) Anti-glucan antibodies
ZA200806053B (en) Anti-EphB4 antibodies and methods using same
GB0505620D0 (en) Methods and materials therefor
ZA200702281B (en) IRTA-4 antibodies and their uses
ZA200705716B (en) IRTA-2 antibodies and their uses
GB0507219D0 (en) Antibody and uses thereof
GB0507272D0 (en) Antibody and uses thereof
GB0518875D0 (en) Methods and means